Key result
Cascade screening for Duchenne muscular dystrophy left 16% to 49% of 1st-degree relatives and 48% to 65% of more distant relatives untested across two UK genetics centers.
Why the study?
Does cascade screening effectively identify all potential female carriers of Duchenne muscular dystrophy?
Observational (n=2,066)
Yes
Does cascade screening effectively identify all potential female carriers of Duchenne muscular dystrophy?
Despite efforts to offer extended cascade screening, a significant number of potential DMD carriers remain unaware of their reproductive and cardiomyopathy risks.
Answers are grounded in this paper and cite their sources.
Cascade screening leaves many at-risk DMD relatives untested; leaves open whether enhanced protocols can achieve comprehensive carrier identification.
Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease caused by mutations in the gene that encodes the protein dystrophin. Approximately 2 of 3 affected boys inherit their mutation from their carrier mother whereupon other female relatives are at risk of carrying the mutation. Female carriers are also at risk of developing cardiomyopathy and regular cardiac screening is recommended. Clinical genetics services offer genetic counselling and carrier tests for consenting relatives of DMD patients known as 'cascade screening'. We retrospectively analysed data from two genetics centres, West of Scotland and South East Thames where the latter centre operated a computer-held DMD register. Over the period, 1971-2008, a total of 843 potential carriers, in 195 West of Scotland families, were tested: 16% of 1st degree relatives and 48% of 2nd degree and more distant relatives were not tested. In South East Thames, a total of 1223 potential carriers in 349 families were tested: 49% of 1st degree and 65% of 2nd degree and more distant relatives were not tested. These data are similar to Becker muscular dystrophy/DMD carrier screening results recently reported from the Netherlands. Retrospective results from three countries indicate that despite efforts to offer extended cascade screening, significant numbers of potential carriers of DMD remain unaware of their reproductive and health risks.
No takes yet. Share an insight, caveat, or question.
McGowan et al. (2012) conducted an observational in Duchenne muscular dystrophy (n=2,066). Cascade screening was evaluated on Proportion of potential carriers not tested. Cascade screening for Duchenne muscular dystrophy left 16% to 49% of 1st-degree relatives and 48% to 65% of more distant relatives untested across two UK genetics centers.
Synapse has enriched 10 related papers. Consider them for comparative context: